|
A Study of 1592U89 Combined with Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on A Study of 1592U89 Combined with Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Study of 1592U89 Combined with Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs Clinical research trials and A Study of 1592U89 Combined with Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as A Study of 1592U89 Combined with Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs. A Study of 1592U89 Combined with Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A Study of 1592U89 Combined with Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs clinical trial. Human subjects often receive the most effective healthcare possible for their A Study of 1592U89 Combined with Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of 1592U89 Combined with Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs  A Study of 1592U89 Combined with Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
A Study of 1592U89 Combined with Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
For Condition: HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: To obtain preliminary evidence of antiretroviral activity of 1592U89 when administered in combination with other specific NRTI agents in NRTI experienced patients and to assess the safety and tolerance of multiple oral doses of 1592U89 when administered in combination with specific marketed NRTIs.
Details: Patients will all receive oral doses of 1592U89 in combination with protocol specific current antiretroviral therapy. The treatment groups will be assigned based on each subject's previous NRTI experience. The study medication is self administered and all evaluations will be performed on an outpatient basis. Patients will be seen at day 0 and weeks 2, 4, 12, 16, 20 and 24.
Eligibility:
Study Type: Interventional, Treatment, Safety Study
Minimum Age/Maximum Age: 13 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - CD4+ cell count >= 100 /mm3. - Plasma HIV RNA >= 30,000 copies/ml. - Study participants may be recruited from all clinical categories, provided they do not meet any of the exclusion criteria. - Parent or legal guardian to sign written, informed consent for patients under the age of 18. Exclusion Criteria Co-existing Condition: Patients with any of the following symptoms or conditions are excluded: - Patients with active or ongoing AIDS-defining opportunistic infection or disease. NOTE: - For this study, a CD4+ cell count <= 200 cells/mm3 in the absence of any other AIDS defining indicator condition is not considered an AIDS defining event. - Malabsorption syndrome or other gastrointestinal dysfunction that might interfere with drug absorption. - Patients with life threatening infection or other serious medical conditions whose participation may compromise patient safety. Concurrent Medication: Excluded: - Treatment with cytotoxic chemotherapeutic agents within the 24 weeks of the study. - Patients receiving other investigational drugs. - Foscarnet therapy or therapy with other agents with documented activity against HIV in vitro. - Treatment with immunomodulators. - Patients on methadone. Concurrent Treatment: Excluded: - Treatment with radiation therapy within the 24 weeks of the study. NOTE: - Localized radiation therapy may be permitted following consultation with the sponsor. Patients with any of the following prior conditions are excluded: - Subjects with a history of lymphoma. - Subjects with a history of clinically apparent pancreatitis or hepatitis within the last 6 months. Prior Medication: Excluded: - Treatment with any antiretroviral therapy with NRTIs (alone or in combination) other than those defined for each treatment group. - Treatment with any non-nucleoside RT inhibitors or protease inhibitors. - Treatment with cytotoxic chemotherapeutic agents within 1 month prior to study entry. - Investigational HIV vaccine within the past 3 months. - Immunomodulating agents such as systematic corticosteroids, interleukins, thalidomide, anticytokine agents, anti-oxidants or interferons within 1 month of study entry. Prior Treatment: Excluded: - Treatment with radiation therapy within 1 month of entry. Risk Behavior: Excluded: Patients with current alcohol or illicit drug use that, in the opinion of the principal investigator, may interfere with the patient's ability to comply with the study protocol.
Total Enrollment: 40
Location and Contact Information:
Univ of Kentucky Med Ctr
Lexington, Kentucky, 40536
United States
ViRx Inc
San Francisco, California, 94109
United States
Beth Israel Med Ctr
New York City, New York, 10003
United States
IDC Research Initiative
Altamonte Springs, Florida, 32701
United States
AIDS Research Consortium of Atlanta
Atlanta, Georgia, 30308
United States
Marin County Specialty Clinic
Greenbrae, California, 94904
United States
Kraus Med Partners
Los Angeles, California, 90036
United States
North Broward Hosp District
Ft. Lauderdale, Florida, 33316
United States
Additional Information:
Study ID Numbers: 238C; CNAA 2003
Study Start Date:
Record last reviewed: April 1997
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002364
Other Hiv Infections Studies:
1. A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines
2. Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients with CD4 Cell Counts of at Least 350 Cells/mm3
3. Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.
4. A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation
5. A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects
Related Studies:
Other HIV Infections Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
A Study of 1592U89 Combined with Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
|
|
|
|
|
|
|
|
